NEW YORK (GenomeWeb) – Lucigen has raised $2.2 million in a private financing round, its CEO confirmed to GenomeWeb today.

The Middleton, Wisc.-based firm disclosed the financing in a regulatory document filed with the US Securities and Exchange Commission this week. In an email, Lucigen Chairman and CEO Ralph Kauten said that the financing is an extension of a private stock placement completed in January that brought in $2 million. According to this week's SEC document, Lucigen is targeting $2.5 million in the round in total.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.